N4P
NEUTRALN4 Pharma to Present at ShareSoc Growth Company Seminar
The biotech company will present on its Nuvec® gene delivery system at an upcoming investor event.
N4 Pharma
0.5200GBX
-0.95%
Market Cap
4.33M
Volume
486.27k
33% of avg
P/E Ratio
NaN
EPS (TTM)
Beta
0.27
Day Range
0.5000p - 0.5500p
52 Week Range
0.3500p0.5200p0.8000p
0.5200p
Upcoming Events
N4P
NEUTRALN4 Pharma Shares New Article on Nuvec®'s Potential in RNA Therapeutics
The biotech company has published a new article highlighting the potential of its Nuvec® gene delivery system for RNA therapeutics.
N4P
NEUTRALN4 Pharma Announces Investor Webinar
The biotech company is hosting an investor webinar to provide a strategic update on the development of its Nuvec® gene delivery system.
N4P
NEUTRALN4 Pharma Appoints New Non-Executive Director
The biotech company has appointed a new non-executive director to its board, representing its largest shareholder.
N4P
NEUTRALN4 Pharma Provides AGM Update on Nuvec® Platform Progress
The biotech company updates on the development of its Nuvec® gene delivery system, highlighting upcoming work to strengthen the commercial data package.
N4P
NEUTRALN4 Pharma to Host Investor Insight Event
The biotech company is hosting an investor event to provide updates on its Nuvec® gene delivery system and pipeline.
N4P
BADN4 Pharma Reports Progress in Pre-Clinical Studies Amid Continued Losses
The pre-clinical biotech firm reported progress in its studies but continues to face financial challenges with ongoing losses and a decreasing cash position, highlighting the risks inherent in early-stage pharmaceutical development.
N4P
NEUTRALN4 Pharma Establishes New Senior Leadership Team
The biotech company has formed a new senior leadership team to support its strategic and scientific objectives, including experts in drug development, commercial strategy, and manufacturing.
N4P
NEUTRALN4 Pharma Announces Director Dealings
The healthcare company has announced a change in major shareholdings.
N4P
NEUTRALN4 Pharma Plc Announces Director Dealings
The healthcare company has announced a transfer of shares between two of its subsidiaries.